← Leaderboards
Antony Dimitrov
Profectus Biosciences, Inc.
$5,981,560
Attributed
$10,828,681
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2007–15$2.5M$1.9M$1.3M$625K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$10,828,681 · 5
By mechanism
R01$9,694,243 · 2
R56$625,704 · 1
R43$508,734 · 2
Top collaborators
- Timothy R Fouts9 shared
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseVirusViralMortality Vital StatisticsClinical TrialsPreventBaseMorbidity - Disease RateVirus DiseasesCessation Of LifeAnimalsCharacteristicsSafetyPreparationCell LineProductionCyclic GmpDisease OutbreaksFerretsAnimal ModelAerosolsFundingAnimal EfficacyAdverse Event
Grant awards (12)
Development of sG as a human vaccine against Nipah/Hendra$1,035,051
R01 · FY2015 · AI
Preclinical Development of m102.4, a Human Anti-Hendra and Nipah Antibody$984,776
R01 · FY2015 · AI
Preclinical Development of m102.4, a Human Anti-Hendra and Nipah Antibody$1,182,666
R01 · FY2014 · AI
Development of sG as a human vaccine against Nipah/Hendra$970,588
R01 · FY2014 · AI
Preclinical Development of m102.4, a Human Anti-Hendra and Nipah Antibody$1,039,531
R01 · FY2013 · AI
Development of sG as a human vaccine against Nipah/Hendra$990,669
R01 · FY2013 · AI
Development of sG as a human vaccine against Nipah/Hendra$1,306,446
R01 · FY2012 · AI
Preclinical Development of m102.4, a Human Anti-Hendra and Nipah Antibody$1,097,778
R01 · FY2012 · AI
Preclinical Development of m102.4, a Human Anti-Hendra and Nipah Antibody$1,086,738
R01 · FY2011 · AI
Evaluating the in vivo Efficacy of CD4i Antibody, m9$625,704
R56 · FY2010 · AI · contact PI
Rapamycin enhanced efficacy of small-molecule HIV entry inhibitors$293,564
R43 · FY2008 · AI · contact PI
Rapamycin Enhanced Efficiency of Anti-HIV Antibodies$215,170
R43 · FY2007 · AI · contact PI